home / stock / bold / bold news

BOLD News and Press, Audentes Therapeutics Inc. From 02/27/19

Stock Information
Company Name: Audentes Therapeutics Inc.
Stock Symbol: BOLD
Market: NASDAQ
Website: boundlessbio.com
Menu
BOLD BOLD Quote BOLD Short BOLD News BOLD Articles BOLD Message Board
Get BOLD Alerts

News, Short Squeeze, Breakout and More Instantly...
BOLD - Audentes Therapeutics beats by $0.07

Audentes Therapeutics (NASDAQ: BOLD ): Q4 GAAP EPS of -$0.84 beats by $0.07 . More news on: Audentes Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...

BOLD - Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update

SAN FRANCISCO , Feb. 27, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today reported its finan...

BOLD - Notable earnings after Wednesday's close

AEGN , ALEX , AMED , ANSS , APA , ATSG , AYX , BEL , BGNE , BILI , BKNG , BOLD , BOX , CABO , CCRN , CHDN , COLL , CRC , CVNA , CWK , DAR , ECPG , ERI , ESTC , ESV , FG , FIT , FOE , FTAI , FTSI , GEF , GKOS , HGV , HHC , HPQ , ITRI , KRA , KW , LADR ,...

BOLD - GE, DHR, SGMO among premarket gainers

Spark Therapeutics ONCE  +121%  on being acquired by Roche Holding. More news on: Phoenix New Media Limited, China Internet Nationwide Financial Services Inc., uniQure N.V., Stocks on the move, Read more ...

BOLD - Roche takeout of Spark Therapeutics stokes gene therapy players

Certain gene therapy stocks are up premarket in reaction to Roche's $4.8B bid for Spark Therapeutics. More news on: bluebird bio, Inc., Solid Biosciences, Inc., CRISPR Therapeutics, Healthcare stocks news, Stocks on the move, , Read more ...

BOLD - Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019

SAN FRANCISCO , Feb. 21, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference c...

BOLD - FDA finalizes guidance for expedited review of cell and gene therapy applications

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...
BOLD - Report: Developing Opportunities within Dunkin' Brands Group, Murphy Oil, NII, Audentes Therapeutics, RealNetworks, and MDC Partners - Future Expectations, Projections Moving into 2019

NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Dunkin' Brands Group, Inc. (NASDAQ:DNKN), Murphy Oil Corporation (NYSE...

BOLD - Audentes advancing gene therapy AT132

Audentes Therapeutics (NASDAQ: BOLD ) continues its progress towards the submission of its U.S. marketing application for gene therapy AT132 for X-linked myotubular myopathy (XLMTM). More news on: Audentes Therapeutics, Healthcare stocks news, Read more ...

BOLD - Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation

SAN FRANCISCO , Jan. 31, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today provided an update...
Previous 10 Next 10